

Curriculum Vitae: updated January 11, 2023

I. IDENTIFYING DATA

Name Lawrence Fung, M.D., Ph.D.
Current Position Assistant Professor, Department of Psychiatry & Behavioral Sciences
Current Affiliation Stanford University

II. EDUCATION HISTORY

Colleges and Universities Attended

1993 B.S. with Honors, Chemical Engineering, University of California, Berkeley
1996 M.S.E., Chemical Engineering, Johns Hopkins University
1998 Ph.D., Chemical Engineering, Cornell University (lab of W. Mark Saltzman, Ph.D.)
2009 M.D., George Washington University School of Medicine

Residency and Fellowship Training

2009 – 2010 Internship, General Psychiatry, Stanford University School of Medicine
2010 – 2013 Residency, General Psychiatry, Stanford University School of Medicine
2012 - 2013 Postdoctoral Research Fellowship in Child Psychiatry & Development
Stanford University School of Medicine (lab of Allan L. Reiss, M.D.)
2012 – 2014 Fellowship in Child & Adolescent Psychiatry
Stanford University School of Medicine

Board Certification

2013 Psychiatry, American Board of Psychiatry and Neurology
2015 Child & Adolescent Psychiatry, American Board of Psychiatry and
Neurology

III. EMPLOYMENT

Academic Appointments:

07/01/2019 – present Assistant Professor of Psychiatry (University Medical Line)
Stanford University School of Medicine, Stanford, CA
06/01/2018 – 06/30/2019 Clinical Assistant Professor of Psychiatry
Stanford University School of Medicine, Stanford, CA

01/01/2015 – 05/31/2018 Instructor of Psychiatry
Stanford University School of Medicine, Stanford, CA

Other Appointments:

2018 – present Director, Stanford Neurodiversity Project
Stanford University School of Medicine, Stanford, CA

2018 – present Director, Neurodiversity Clinic (formerly Adult Neurodevelopment
Clinic)
Stanford Healthcare, Stanford, CA

2015 – present Staff Psychiatrist, Autism & Developmental Disabilities Clinic
Lucile Packard Children’s Hospital, Stanford, CA

2017 – 2019 Staff Psychiatrist, Stanford In-patient Unit at Mills Peninsula Hospital

2015 – 2018 Staff Psychiatrist, Pediatric Neuropsychopharmacology Clinic
Lucile Packard Children’s Hospital, Stanford, CA

2009 – 2014 Intern (2009-2010); Resident (2010-2012); Child & Adolescent Psychiatry
Fellow (2012-2014); Postdoctoral Research Scholar (2013-14)
Stanford University School of Medicine
Department of Psychiatry & Behavioral Sciences, Stanford, CA

2005 – 2009 Consultant
Advanced Pharmacokinetic Consulting
Oakton, VA

2001 – 2005 Associate Director of Pharmacokinetics (2004-05); Research Fellow
II/Group Leader (2003-04); Research Fellow I/Group Leader (2001-02)
Neurogen Corporation (acquired by Ligand Pharmaceuticals in 2009)
Department of Drug Metabolism
Branford, CT

1998 – 2001 Research Investigator II (2000 – 2001); Research Investigator I (1998 –
2000)
Bristol-Myers Squibb Company Pharmaceutical Research Institute
Discovery Metabolism and Pharmacokinetics, Wallingford, CT

IV. HONORS AND AWARDS

2000-2001 Spot Awards, Bristol-Myers Squibb Pharmaceutical Research Institute
2006 General Clinical Research Center Medical Student Scholar, Children’s National
Medical Center, Washington, DC
2010 American Psychiatric Institute on Research and Education (APIRE) / Janssen Resident
Psychiatric Research Scholar

- 2010 American Academy of Child & Adolescent Psychiatry (AACAP) Outstanding General Psychiatry Resident Award – previously Educational Outreach Program Award
- 2010 Elected to Stanford Society of Physician Scholars
- 2011 National Institute of Mental Health (NIMH) Outstanding Resident Award
- 2011 Academy of Psychosomatic Medicine Trainee Travel Award
- 2011 NIMH-sponsored Brain Camp III participant
- 2012 Miller Award for the Best Paper By a Psychiatric Resident, Stanford University
- 2012 Nominee, National Institutes of Health Director’s Early Independence Award (selected from Stanford University-wide search)
- 2013 Nominee, Burroughs Wellcome Fund Career Awards for Medical Scientists (selected from Stanford University-wide search)
- 2013 AACAP Pilot Research Award
- 2013 Finalist, National Institutes of Health Director’s Early Independence Award (project title: *GABAergic Cytoarchitectonics, Neuroanatomy, and Structural Connectivity in Autism Spectrum Disorder and Fragile X Syndrome*)
- 2013 Runner-up in Resident Poster Competition, Session on “Community Service, Curriculum Development and Educational, Psychosocial and/or Biomedical Research”, Annual Meeting of the American Psychiatric Association
- 2013 Scholar, Career Development Institute for Psychiatry
- 2015 American College of Neuropsychopharmacology (ACNP) Travel Award
- 2016 Clinical Investigator Award / Mentored Clinical Scientist Research Career Development Award (K08), National Institute of Mental Health
- 2016 Young Investigator Award, International Symposium on Functional NeuroReceptor Mapping of the Living Brain
- 2017 Society of Biological Psychiatry (SOBP) Travel Fellowship Award
- 2018 Elected as Associate Member of ACNP
- 2019 Elected as Fellow of American Psychiatric Association
- 2020 Faculty Professional & Leadership Development Award, Department of Psychiatry and Behavioral Sciences, Stanford University
- 2020 Chairman’s Award on Community Commitment and Engagement, Department of Psychiatry and Behavioral Sciences, Stanford University

V. BIBLIOGRAPHY

Peer-reviewed original research (30 total, 1 submitted)

1. Strasser JF, **Fung LK**, Eller S, Grossman SA, Saltzman WM. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. *Journal of Pharmacology and Experimental Therapeutics*. 1995 Dec; 275(3): 1647-1655. PMID: 8531140.
2. **Fung LK**, Shin M, Tyler B, Brem H, Saltzman WM. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. *Pharmaceutical Research*. 1996 May; 13(5): 671-678. PMID: 8860421.
3. **Fung LK**, Ewend MG, Sills A, Sipos EP, Thompson R, Watts M, Colvin OM, Brem H, Saltzman WM. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. *Cancer Research*. 1998 Feb; 58(4): 672-684. PMID: 9485020.

4. Fura A, Harper TW, Zhang H, **Fung L**, Shyu WC. Shift in pH of biological fluids during storage and processing: effect on bioanalysis. *Journal of Pharmaceutical and Biomedical Analysis*. 2003 Jul; 32(3): 513-522. PMID: 14565556.
5. Dubowchik GM, Michne JA, Zuev D, Schwartz W, Scola PM, James CA, Ruediger EH, Pin SS, Burris KD, Balanda LA, Gao Q, Wu D, **Fung L**, Fiedler T, Browman KE, Taber MT, Zhang J. 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy. *Bioorganic and Medicinal Chemistry Letters*. 2003 Nov; 13(22): 3997-4000. PMID: 14592493.
6. Han X, Michne JA, Pin SS, Burris K, Balanda LA, **Fung LK**, Fiedler T, Browman KE, Taber MT, Zhang J, Dubowchik GM. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*. 2005 Sep; 15(17): 3870-3873. PMID: 15982881.
7. Han X, Pin SS, Burris K, **Fung LK**, Huang S, Taber MT, Zhang J, Dubowchik GM. Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*. 2005 Sep; 15(18): 4029-4032. PMID: 15990298.
8. Blum CA, Zheng X, Brielmann H, Hodgetts KJ, Bakthavatchalam R, Chandrasekhar J, Krause JE, Cortright D, Matson D, Crandall M, Ngo CK, **Fung L**, Day M, Kershaw M, De Lombaert S, Chenard BL. Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution. *Bioorganic and Medicinal Chemistry Letters*. 2008 Aug 15;18(16):4573-7. PMID: 18662872.
9. Mattai A, **Fung L**, Bakalar J, Overman G, Tossell J, Miller R, Rapoport J, Gogtay N. Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children. *Human Psychopharmacology*. 2009 Oct; 24(7):584-9. PMID: 19743394.
10. Vrudhula VM, Dasgupta B, Pin SS, Burris KD, Balanda LA, **Fung LK**, Fiedler T, Browman KE, Taber MT, Zhang J, Macor JE, Dubowchik GM. Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R). *Bioorganic and Medicinal Chemistry Letters*. 2010 Mar 15;20(6):1905-9. PMID: 20185312.
11. Hardan AY, **Fung LK**, Amin H. Risperidone: Switching from brand-name to generic. *Journal of Child and Adolescent Psychopharmacology* 2010. 20(5):457-458. PMID: 20973719.
12. Hodgetts KJ, Ge P, Yoon T, Lombaert SD, Brodbeck R, Gulianello M, Kieltyka A, Horvath RF, Kehne JH, Krause JE, Maynard GD, Hoffman D, Lee Y, **Fung L**, Doller D. Discovery of N-(1-Ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): An Orally Active Corticotropin Releasing Factor-1 (CRF-1) Receptor Antagonist. *Journal of Medicinal Chemistry*. 2011 Jun 23;54(12):4187-4206. PMID: 21618986.
13. Hardan AY, **Fung LK**, Libove R, Obukhanych TV, Nair S, Herzenberg LA, Frazier TW, Tirouvanziam R. A randomized, placebo-controlled, double-blind trial of N-Acetylcysteine in children with autism. *Biological Psychiatry*. 2012 Jun 1;71(11):956-61. PMID: 22342106.
14. **Fung LK**, Chahal L, Libove R, Bivas R, Hardan AY. A retrospective review of the effectiveness of aripiprazole in the treatment of sensory abnormalities in autism. *Journal of Child and Adolescent Psychopharmacology*. 2012 Jun;22(3):245-8. PMID: 22537360.
15. **Fung LK**, Akil M, Widge A, Roberts LW, Etkin A. Attitudes toward neuroscience education among psychiatry residents and fellows. *Academic Psychiatry*. 2014 Apr;38(2):127-34. PMID: 24493359.

16. **Fung LK**, Libove R, Phillips J, Haddad F, Hardan AY. Brief Report: An open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder. *Journal of Autism & Developmental Disabilities*. 2014 Nov;44(11):2971-7. PMID: 24849255.
17. **Fung LK**, Akil M, Widge A, Roberts LW, Etkin A. Attitudes towards neuroscience education in psychiatry: a national multi-stakeholder survey. *Academic Psychiatry*. 2015 Apr;39(2):139-46. PMID: 25001432.
18. Hardan AY, **Fung LK**, Frazier T, Berquist SW, Minshew NJ, Keshavan MS, Stanley JA. A proton spectroscopy study of white matter in children with autism. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2015 Nov 16;66:48-53. PMID: 26593330.
Analyzed imaging data and wrote manuscript.
19. **Fung LK**, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, Coury D, Whitaker A, Veenstra-Vanderweele J, Hardan AY. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. *Pediatrics*. 137(s2) February 2016:e20152851. PMID: 26908468.
20. Palner M, Beinat C, Banister S, Zanderigo F, Park J, Shen B, Hjoernevik T, **Fung L**, Chin FT. Effects of common anesthetic agents on [¹⁸F]flumazenil binding to the GABA_A receptor. *European Journal of Nuclear Medicine and Molecular Imaging Research*. 2016 Dec;6(1):80. PMID: 27826950.
Designed study and revised manuscript.
21. Parker KJ, Oztan O, Libove RA, Mohsin N, Karhson DS, Sumiyoshi RD, Summers JE, Hinman KE, Motonaga KS, Phillips JM, Carson DS, **Fung LK**, Garner JP, Hardan AY. A Randomized Controlled Pilot Trial of Intranasal Vasopressin Treatment for Social Deficits in Children with Autism. *Science Translational Medicine*. 2019 May 8;11(491). pii: eaau7356. PMID: 31043522.
Contributed to assess participants before and after vasopressin treatment.
22. Schuck R, Flores R, **Fung LK**. Sex/Gender Differences in Symptomology and Camouflaging in Adults with Autism Spectrum Disorder. *Journal of Autism & Developmental Disabilities*. 2019 Jun;49(6):2597-2604. PMID: 30945091.
23. Leyden J, **Fung L**, Frick S. Autism and toe-walking: are they related? Trends and treatment patterns from 2005-2016. *Journal of Children's Orthopaedics*. 2019 Aug 1;13(4): 340–45. PMID: 31489038.
Contributed to study design and manuscript preparation.
24. Scanlan J, Eddy A, Thomas T, Tan T, Chen YP, Watters PA, Fieldhouse M, **Fung L**, and Girdler S. Neurodiverse Knowledge, Skills and Ability Assessment for Cyber Security. *Australasian Conference on Information Systems (ACIS) Proceedings*. 2020.
25. **Fung LK**, Flores R, Gu M, Sun K, James D, Schuck R, Jo B, Lee BC, Jung JH, Kim SE, Saggari M, Sacchet M, Warnock G, Khalighi MM, Spielman D, Chin F, Hardan AY. Thalamic and prefrontal GABA concentrations but not GABA_A receptor densities are altered in high-functioning adults with autism spectrum disorder. *Molecular Psychiatry*. 2021 May;26(5):1634-1646. doi: 10.1038/s41380-020-0756-y. PMID: 32376999.
26. Chew L, Sun KL, Sun W, Tang H, Wang Z, Rajadas J, Flores RE, Arnold E, Jo B, **Fung LK**. Association of Serum Allopregnanolone with Restricted and Repetitive Behaviors in High-Functioning Adult Males with Autism. *Psychoneuroendocrinology*. 2021 Jan;123:105039. doi: 10.1016/j.psychneu.2020.105039. Online ahead of print. PMID: 33161257.

27. Ayub R, Sun KL, Flores RE, Lam VT, Jo B, Saggarr, M, **Fung LK**. Thalamocortical Connectivity is Associated with Autism Symptoms in High-Functioning Adults with Autism and Typically Developing Adults. *Translational Psychiatry*. 2021 Feb 3;11(1):93. doi: 10.1038/s41398-021-01221-0. PMID: 33536431.
28. James D, Lam VT, Jo B, **Fung LK**. Region-Specific Associations between GABA_A Receptor Binding and Cortical Thickness in High-Functioning Autistic Adults. *Autism Research*. 2022 Mar 8; 15(6)1068-1082. doi: 10.1002/aur.2703. PMID: 35261207.
29. Cai RY, Gibbs V, Love A, Robinson A, **Fung L**, Brown L. “Self-compassion changed my life”: The self-compassion experiences of autistic and non-autistic adults and its relationship with mental health and psychological wellbeing. *Journal of Autism & Developmental Disabilities*. Online ahead of print. July 29, 2022. PMID: 35904649

Contributed to manuscript preparation.

Peer-reviewed original research (submitted)

30. James D, Lam VT, Jo B, **Fung LK**. Sex Differences in the Relationship Between Cortical Thickness and Sensory Motor Symptoms in Autistic Adults.

Other peer-reviewed publications (9 total; 1 submitted)

1. Mak M, **Fung L**, Strasser JF, Saltzman WM. Distribution of drugs following controlled delivery to the brain interstitium. *Journal of Neuro-Oncology*. 1995 Nov; 26(2): 91-102. PMID: 8787851.
2. **Fung LK**, Saltzman WM. Polymeric implants for cancer chemotherapy. *Advanced Drug Delivery Reviews*. 1997 Jul; 26(2-3): 209-230. PMID: 10837544.
3. **Fung LK**, Quintin E, Haas BW, and Reiss AL. Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndrome. *Current Opinion in Neurology*. 2012 Apr; 25(2): 112–124. PMID: 22395002.
4. **Fung LK** and Hardan AY. Autism and DSM-5: implications to patients, families, clinicians, and researchers. *Journal of Asian Psychiatry*. 2014 Oct;11:93-7. PMID: 25219947.
5. **Fung LK** and Hardan AY. Developing medications targeting glutamatergic dysfunction in autism: progress to date. *CNS Drugs*. 2015 Jun; 29(6):453-63. PMID: 26104862.
6. McGuire K, **Fung LK**, Hagopian L, Vasa RA, Mahajan R, Bernal P, Silberman AE, Wolfe A, Coury D, Veenstra-Vanderweele J, Hardan AY, Whitaker A. Irritability and problem behavior in autism spectrum disorder: a practice pathway for pediatric primary care. *Pediatrics*. 137(S2), February 2016:e20152851. PMID: 26908469.

Contributed to the development of practice pathway and manuscript preparation.

7. **Fung LK** and Reiss AL. Moving towards integrative, multi-dimensional research in modern psychiatry: lessons learned from fragile X syndrome. *Biological Psychiatry*. 2016 Jul 15;80(2):100-11. PMID: 26868443.
8. Morris I, Matta C, **Fung LK**. A Scoping Review of Peer Mentoring Programs for Autistic College Students. *Review Journal of Autism and Developmental Disabilities*. Published: 20 May 2022. <https://doi.org/10.1007/s40489-022-00325-7>
9. Clarke L, **Fung, LK**. The impact of educational interventions on physician’s knowledge and attitudes towards treating adults on the autism spectrum: a systematic review. 2022. *Autism*. 26(7): 1626-1640. <https://doi.org/10.1177/13623613221102016> PMID: 35698749.

Other peer-reviewed publications (submitted or in preparation)

10. Karsting H, James D, **Fung LK**. Autism Training Programs for Providers Supporting Autistic Adults: A Scoping Review.

Non-Peer-reviewed Articles (12 total)

1. Froehlich W and **Fung LK**. Autism spectrum and neurodevelopmental disorders: clinical update for psychiatrists. *Psychiatric Times*. 2012 Dec; 29(11).
2. **Fung LK**. One step closer to shining light in humans? *Science Translational Medicine*. 23 Mar 2016: Vol. 8, Issue 331, pp. 331ec48.
3. **Fung LK**. New neural measures signal autism. *Science Translational Medicine*. 04 May 2016: Vol. 8, Issue 337, pp. 337ec73.
4. **Fung LK**. Does a mother's voice influence a child's social communication abilities? *Science Translational Medicine*. 15 Jun 2016: Vol. 8, Issue 343, pp. 343ec95.
5. **Fung LK**. A sneak peek at personalized medicine in autism? *Science Translational Medicine*. 27 Jul 2016: Vol. 8, Issue 349, pp. 349ec119.
6. **Fung LK**. Can imaging predict future suicidal behavior? *Science Translational Medicine*. 7 Sep 2016: Vol. 8, Issue 355, pp. 355ec143.
7. **Fung LK**. New genetic insights into brain size. *Science Translational Medicine*. 19 Oct 2016: Vol. 8, Issue 361, pp. 361ec166.
8. **Fung LK**. Imaging serotonin reuptake in the living brain. *Science Translational Medicine*. 30 Nov 2016: Vol. 8, Issue 367, pp. 367ec191. PMID: 27903859
9. **Fung LK**. A sterile animal model for neuroinflammation? *Science Translational Medicine*. 18 Jan 2017: Vol. 9, Issue 373, DOI: 10.1126/scitranslmed.aal4994. PMID: 28100836
10. Gade S, Hjørnevik T, Park JH, Shen B, Gu M, Tseng J, Barbosa D, Leuze C, Pitteri S, Jung J, Lee BC, Kim SE, McNab J, Spielman D, Hall SS, **Fung LK**, Chin FT. The first awake simultaneous PET-MR study of an adult with fragile X syndrome: A case report. *Preprints*. 2021. DOI: <https://doi.org/10.21203/rs.3.rs-189580/v1>
11. **Fung LK**. Neurodiversity and Opportunities in Psychiatry. *Psychiatric Times*. 2022 Jan; 57(1)30.
12. **Fung, LK**, Ulrich, TL, Fujimoto, KT, Taheri, M. Neurodiversity: An Invisible Strength? *The Journal of The Minerals, Metals & Materials Society*. 74, 3200–3202 (2022). <https://doi.org/10.1007/s11837-022-05454-2>

Book (1 total)

1. **Fung LK**: *Neurodiversity: from Phenomenology to Neurobiology and Enhancing Technologies*. (2021) American Psychiatric Association Publishing, Arlington, VA.

Book Chapters (10 total)

1. **Fung LK** and Reiss AL. Chapter 8. Genetic disorders associated with the autism spectrum disorder phenotype. In McDougle C: *Primer on Autism Spectrum Disorder*. (2016) Oxford University Press, New York, NY.
2. **Fung LK** and Hardan AY. Corpus Callosum and Autism. In Casanova M: *Autism Imaging and Devices*. (2017) CRC Press, Boca Raton, FL.

3. **Fung LK**. Chapter 19. Autism Spectrum Disorder. In Roberts LW: *University Student Mental Health: A Guide for Psychiatrists, Psychologists, and Leaders Serving Higher Education*. First Edition. (2018) American Psychiatric Association Publishing, Arlington, VA.
4. **Fung LK** and Hardan AY. Chapter 4. Oxidative Stress and the Role of N-acetylcysteine in Psychiatric Disorders. In Frye R and Berk M: *The Therapeutic Use of NAC in Medicine*. (2019) Adis Publications, Springer Healthcare, Auckland, New Zealand.
5. Hong DS, **Fung LK** and Hardan AY. Chapter 9. Neurodevelopmental Disorders. In Roberts LW: *American Psychiatric Association Publishing Textbook of Psychiatry*. Seventh Edition. (2019) American Psychiatric Association Publishing, Arlington, VA.
6. **Fung LK** and Doyle N. Chapter 1. Neurodiversity: The New Diversity. In **Fung LK**: *Neurodiversity: from Phenomenology to Neurobiology and Enhancing Technologies*. (2021) American Psychiatric Association Publishing, Arlington, VA.
7. **Fung LK**. Chapter 4. Strengths-Based Model of Autism. In **Fung LK**: *Neurodiversity: from Phenomenology to Neurobiology and Enhancing Technologies*. (2021) American Psychiatric Association Publishing, Arlington, VA.
8. **Fung LK**. Chapter 5. Strengths-Based Model of Attention Deficit Hyperactivity Disorder. In **Fung LK**: *Neurodiversity: from Phenomenology to Neurobiology and Enhancing Technologies*. (2021) American Psychiatric Association Publishing, Arlington, VA.
9. **Fung LK**. Chapter 7. Neurobiology of Neurodiversity. In **Fung LK**: *Neurodiversity: from Phenomenology to Neurobiology and Enhancing Technologies*. (2021) American Psychiatric Association Publishing, Arlington, VA.
10. Hegarty JP, **Fung LK** and Hardan AY. Chapter 32. N-Acetylcysteine. In Hollander E, Hagerman RJ, and Ferretti CJ: *Textbook of Autism Spectrum Disorders*. Second Edition. (2022) American Psychiatric Association Publishing, Arlington, VA.

Abstracts (19 of 42 total)

1. **Fung LK**, Sun W, Libove R, Tanaka S, Phillips J, Haddad F, Rajadas J, Hardan AY. Open-Label Study of Pregnenolone in the Treatment of Irritability in Autism Spectrum Disorder – a Post-Hoc Metabolomic Analysis. Presented on November 7, 2015 at the 1st Regional Asia Pacific IMFAR Regional Meeting in Shanghai, China.
2. **Fung LK**, Sun W, Libove R, Tanaka S, Kwa L, Phillips J, Haddad F, Rajadas J, Hardan AY. Pregnenolone in the Treatment of Irritability in Autism Spectrum Disorder – a Post-Hoc Metabolomic Analysis. December 7, 2015 at the 54th Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Florida.
3. Derar N, Alexander S, Bass D, Alcorn D, **Fung LK**, Watkins D, Rosenblatt DS, Cowan TM, Enns GM. Renal Complications in Longitudinal Evaluation of a Patient with Cobalamin G Disease. 2016 ACMG Annual Clinical Genetics Meeting. March 8-12, 2016, Tampa Convention Center, Tampa, Florida.
4. **Fung LK**, Sun W, Libove R, Tanaka S, Phillips J, Rajadas J, Hardan AY. Predicting Response to Pregnenolone Treatment of Irritability in Autism Spectrum Disorder – Preliminary Neurosteroid Metabolomic Analysis. Presented on May 14, 2016 at the International Meeting for Autism Research (INSAR) in Baltimore, Maryland.
5. **Fung LK**, Gu M, Leuze C, Hjoernevik T, Shen B, Park JH, Levine S, Holley D, Jung JH, Lee BC, Kim SE, Khaligi M, Gulaka P, Zaharchuk G, McNab J, Quon A, Spielman D, Chin FT.

Simultaneous Acquisition of GABA_A Receptor Binding Potential by [¹⁸F]Flumazenil-PET and GABA by Magnetic Resonance Spectroscopy. Presented on July 15, 2016 at the International Symposium on Functional NeuroReceptor Mapping of the Living Brain in Boston, Massachusetts.

6. **Fung LK**. Cortisol in Individuals with Autism Spectrum Disorder: Meta-Analysis and Systematic Review. Presented on October 29, 2016 at the Annual Meeting of the American Academy of Child & Adolescent Psychiatry in New York, NY.
7. **Fung LK**, Gu M, Leuze C, Hjoernevik T, Shen B, Park JH, Flores R, Levine S, Holley D, Gandhi H, Park JH, Lee BC, Kim SE, Khaligi M, Gulaka P, Zaharchuk G, McNab J, Quon A, Spielman D, Chin FT. Studying GABA Neurophysiology by Simultaneous [¹⁸F]Flumazenil-Positron Emission Tomography and Magnetic Resonance Spectroscopy. Presented on December 5, 2016 at the 55th Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Florida.
8. Parker K, Oztan O, Libove R, Sumiyoshi R, Summers J, Hinman K, **Fung L**, Motonaga K, Carson D, Phillips J, Garner J, Hardan A. Intranasal Vasopressin Treatment Improves Social Abilities in Children With Autism. Presented on December 6, 2016 at the 55th Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Florida.
9. **Fung LK**, Flores R, Gu M, Leuze C, Hjoernevik T, Shen B, Park JH, Jung JH, Lee BC, Kim SE, McNab J, Spielman D, Chin FT. Interrogating the GABAergic System with Simultaneous [¹⁸F]Flumazenil-Positron Emission Tomography and GABA-Magnetic Resonance Spectroscopy in Healthy Volunteers. Presented on April 2, 2017 in the 13th Conference on Quantification of Brain Function with PET in Berlin, Germany.
10. **Fung LK**, Siebert J, Hardan AY. Immune Response to Pregnenolone Treatment in Adults with Autism Spectrum Disorder – Preliminary Analysis from an Open-Label Study. Presented on May 12, 2017 at the International Meeting for Autism Research (INSAR) in San Francisco, CA.
11. **Fung LK**, Flores R, Gu M, Hjoernevik T, Spielman D, Chin FT. Simultaneous [¹⁸F]Flumazenil-Positron Emission Tomography and GABA-Magnetic Resonance Spectroscopy in Adults with Autism and Healthy Volunteers. Presented on May 18, 2017 at the Society of Biological Psychiatry's 72nd Annual Scientific Program and Convention in San Diego, California.
12. **Fung LK**, Flores R, Liu K, Gu M, Spielman D, Chin FT, Hardan A. Comprehensive Examination of the GABAergic System in Adults with Autism by Simultaneous [¹⁸F]Flumazenil-Positron Emission Tomography and Magnetic Resonance Spectroscopy. Presented on December 4, 2017 at the 56th Annual Meeting of the American College of Neuropsychopharmacology in Palm Springs, California.
13. **Fung LK**, Flores R, Schuck R, Chew L, Gu M, Spielman D, Chin FT, Hardan A. "GABAergic Dysfunction and Socio-communicative Deficits in Adults with Autism Spectrum Disorder". Presented on July 11, 2018 at the International Symposium on Functional NeuroReceptor Mapping of the Living Brain in London, England.
14. **Fung LK**, Flores R, Gu M, Spielman D, Chin FT, Hardan A. Socio-communicative Deficits are Modulated by GABA Concentrations but not GABA_A Receptor Densities in Adults with Autism Spectrum Disorder. Presented on December 11, 2018 at the 57th Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Florida.
15. Leyden J, **Fung LK**, Frick S. "Autism and Toe-walking: Are they related? Trends and treatment patterns from 2005-2016". 2019 POSNA Annual Meeting, May 15-18, 2019 in Charlotte, North Carolina.

16. Ayub R, Flores R, **Fung L**, Sagggar M. Graph theory analysis of multimodal neuroimaging data in high-functioning adults with Autism Spectrum Disorder. Presented at: Society for Neuroscience. October 2019; Chicago, IL.
17. Bruk-Lee, V., Bruyere, S., Doyle, N., **Fung, L.**, Patten, E. Title: Diamond in the rough? Neurodiversity inclusion in practice. Presented virtually at the Society for Industrial and Organizational Psychology Conference 2020. June 18, 2020.
18. Sun KL, Ayub R, Flores RE, Sagggar, M, **Fung LK**. Sex Differences in Resting-State Functional Connectivity in High-Functioning Adults with Autism. Presented virtually on December 9, 2020 at the 59th Annual Meeting of the American College of Neuropsychopharmacology.
19. Miri P, Arora M, Malhotra A, Flory R, Hu S, Lowber A, Goyal I, Nguyen J, Hegarty JP, Kohn M, Schneider D, Culbertson H, Yamins DLK, **Fung L**, Hardan A, Gross JJ, and Marzullo K. 2022. FAR: End-to-End Vibrotactile Distributed System Designed to Facilitate Affect Regulation in Children Diagnosed with Autism Spectrum Disorder Through Slow Breathing. Proceedings of the 2022 CHI Conference on Human Factors in Computing Systems. Association for Computing Machinery, New Orleans LA, USA.

VI. GRANT FUNDING

Current:

04/2020 - 03/2023 No cost extension after 03/2023	Funder: Autism Speaks Mechanism: Adult Transition Research Grant Title: Achieving Steady Work among Adults with Autism through Specialized Employment Program Role: PI
05/2022 - 09/2024	Funder: United States Department of Education Mechanism: The Rehabilitation Services Administration Disability Innovation Fund (DIF) - Career Advancement Initiative Model Demonstration Projects Subcontract from California Department of Rehabilitation (Title of awarded project: Pathways to Success) Title of subcontracted project: Educating California's Employers on Neurodiversity Role: PI
12/01/2022-05/31/2024	Funder: California Department of Developmental Services Mechanism: DDS Employment Grant Title: Training Service Providers to Improve Employment Outcomes of Individuals with Intellectual and Developmental Disabilities Role: PI
07/01/2022-06/30/2027	Funder: National Institutes of Health Mechanism: Autism Centers of Excellence: Centers (P50) Title: Sleep in Autism Spectrum Disorder (Center PI: Joachim Hallmayer, M.D.) Role: PI of Dissemination & Outreach Core

Completed:

2016 – 2020 Funder: National Institute of Mental Health (NIMH) - K08MH111750
Mechanism: K08
Title: GABAergic Neurophysiology in Autism Spectrum Disorder
Role: PI

VII. CLINICAL TRIALS

Achieving Steady Work Among Adults with Autism Through Specialized Employment Program
(April 1, 2020 - April 30, 2023)

VIII. PATENTS

Pending: Methods and Formulations to Treat Serious Behavioral Symptoms in Individuals with
Autism Spectrum Disorder

IX. EDITORIAL SERVICE

Editorial Positions

2016 – 2017 Associate Scientific Advisor, *Science Translational Medicine*
2021 – 2022 Review Editor, *Frontiers in Psychiatry*
2022 – present Associate Editor, *Frontiers in Psychiatry*
2022 – present Associate Editor, *Journal of Autism & Developmental Disabilities*
2023 – present Editorial Board Member, *Neurodiversity*

Ad Hoc Reviewer

2012 – present *Academic Psychiatry*
2014 – present *Biological Psychiatry*
2014 – present *Journal of Autism & Developmental Disabilities*
2015 – present *Journal of Psychiatric Research*
2015 – present *Molecular Autism*
2015 – present *Pediatric Drugs*
2015 – present *Psychopharmacology*
2015 – present *Journal of Pediatrics*
2016 – present *JAMA Psychiatry*
2016 – present *Clinical Medicine Insights – Pediatrics*
2016 – present *CNS Drugs*
2016 – present *Autism Research*
2016 – present *Journal of the American Academy of Child and Adolescent Psychiatry*
2016 – present *Journal of Child Neurology*
2016 – present *Biological Psychiatry – Cognitive Science & Neuroimaging*
2016 – present *Journal of Child Psychiatry*
2017 – present *Research in Autism Spectrum Disorders*
2017 – present *Journal of Neurodevelopmental Disorders*
2018 – present *Brain Connectivity*

2018 – present *PLOS ONE*
 2020 – present *Autism*
 2021 – present *Molecular Psychiatry*
 2021 – present *Nature Communications*
 2021 – present *Journal of Neuroscience Research*
 2022 – present *Neuropsychopharmacology*
 2022 – present *Review Journal of Autism & Developmental Disabilities*

X. SERVICE AS GRANT REVIEWER

2017 Reviewer, *Building University Infrastructure Leading to Diversity Initiative (BUILD) program (funded by the NIH)*
 2019 Reviewer, *Predoctoral Fellowship Grant Review Panel, Autism Speaks, 2019*
 2020 Reviewer, *Autism Research Program CTR-CT-1 panel, Clinical Translational Research Award and Clinical Trial Award, Congressionally Directed Medical Research Programs (CDMRP), United States Department of Defense*
 2021 Reviewer, *Swiss National Science Foundation*

XI. UNIVERSITY ADMINISTRATIVE SERVICE

Committees in the Department of Psychiatry & Behavioral Sciences:

2010 – 2016 Resident Selection Advisory Committee, Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine
 2011 General Psychiatry Curriculum Committee, Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine
 2018 – present Co-Director of Grand Rounds / CME Committee, Department of Psychiatry & Behavioral Sciences, Stanford University

Special Initiative of the Department of Psychiatry & Behavioral Sciences:

2018 – present Director, *Stanford Neurodiversity Project*
 2019 – present Directs the *Neurodiverse Student Support Program at Stanford (Number of neurodiverse Stanford students served > 20)*
 2019 – present Directs the *Neurodiversity at Work Program at Stanford*

- Number of candidates served ~800
- Formal collaborations to build specialized employment program at Google, DPR Construction, Rangan
- Informal collaborations with various departments at Stanford University, including Department of Comparative Medicine, Gene Vector and Virus Core of the Wu Tsai Neuroscience Institute, Stanford Cancer Institute, Hoover Institution

 2019 - present Research, Education, and Advocacy Camp for High Schoolers (SNP REACH) – 2-week immersive neurodiversity design thinking camp for high school students (Summer 2022: 89 students; Summer 2021: 60 students; Summer 2020: 40 students)
 2020 Neurodiversity Design Thinking Workshops – 9-week neurodiversity design thinking workshop for stakeholders, including neurodiverse adults, parents, mental

- health providers, service providers, representatives from the Department of Rehabilitation (Number of participants: ~90)
- 2020 - present Chair, Organizing Committee, Stanford Neurodiversity Summit
- October 17 to 21, 2020; ~3200 registrants
 - November 7 to 9, 2021; ~5200 registrants; free CME Event
 - October 23 to 25, 2022; ~2500 registrants; CME Event

Committees in the Stanford Neurosciences Interdepartmental Program (IDP):

2022 – present Chair, Mental Health Committee

Stanford University School of Medicine:

2016 – 2019 Reviewer and Interviewer, Admissions, Doctor of Medicine program, Stanford University School of Medicine

XII. SERVICE TO PROFESSIONAL ORGANIZATIONS

State and Federal Government Agencies:

- Dec 2021 – present Member, Employment Workgroup, California Department of Developmental Services
- Dec 2021 Member, Technical Working Group (TWG), Advancing Research on Students with Disabilities in Postsecondary Education, Institute of Educational Sciences, United States Department of Education.

Organizations at Stanford:

- 2018 – present Member, Bio-X
- 2019 – present Member, SPARK at Stanford
- 2019 – present Member, Maternal & Child Health Research Institute (MCHRI)
- 2023 – present Member, Wu Tsai Human Performance Alliance

Professional Organizations:

- 2012 – 2015 Member, Irritability Assessment & Treatment Subgroup, Autism Speaks – Autism Treatment Network
- 2014 Symposium Co-chair, “Irritability and Aggression in Autism Spectrum Disorder: Evidence from Characterization to Treatment.” October 24, 2014 at the Annual Meeting of the American Academy of Child & Adolescent Psychiatry in San Diego, CA.
- 2016 Symposium Co-chair, “Anxiety in Individuals with Autism Spectrum Disorder: Clinical Assessment, Biology, and Treatments.” 2016 Annual Meeting of the American Academy of Child & Adolescent Psychiatry in New York, NY.
- 2017 Member, Working Group for the James C Harris MD Developmental Neuropsychiatry Forum, Autism & Intellectual Disabilities Committee, AACAP
- 2018 – present Associate Member, American College of Neuropsychopharmacology
- 2018 – present Board of Directors, Bay Area Autism Consortium

2018 – 2020	Workgroup member, Evidence-Based Practice Pharmacology Workgroup, Autism Speaks
2019	Co-chair, 2 nd Annual Autism at Work Research Workshop. May 29, 2019, Redmond, Washington.
2019 – present	Fellow, American Psychiatric Association
2020 – present	Member, Program Committee, Annual Meeting of the Society of Biological Psychiatry
2021 – present	President, Bay Area Autism Consortium
2022 – present	Research Member, Stanford Center for Precision Mental Health and Wellness

Community Organizations:

2016	Chair, “Accessing ASD Adult Healthcare Panel.” 2016 Annual Meeting of the Autism Society (San Francisco Chapter), Stanford, CA.
2017	Chair, “Hot Topics in Health: Cannabis and Stress.” 2017 Annual Meeting of the Autism Society (San Francisco Chapter), Stanford, CA.
2017	Organizing Committee Member, 2017 Annual Meeting of the Autism Society (San Francisco Chapter), Stanford, CA.
2018	Organizing Committee Member, 2018 Annual Meeting of the Autism Society (San Francisco Chapter), Stanford, CA.
2019	Organizing Committee Member, 2019 Annual Meeting of the Autism Society (San Francisco Chapter), Stanford, CA.
2019 – present	Board of Directors, Autism Asperger’s Spectrum Coalition for Education, Networking and Development (AASCEND)
2020 – present	Board of Directors, Helping Autistic Adults Perform and Excel (HAAPE)
2022 – present	Medical Leadership Committee, Parents Helping Parents

XIII. INVITED PRESENTATIONS (since 2011)

Grand Rounds:

1. “Advancing Pharmacologic Treatments in Autism Spectrum Disorder.” Presented in Grand Rounds, Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine. February 25, 2016.
2. “GABAergic Neurophysiology and Socio-communicative Abilities in High-functioning Adults with Autism Spectrum Disorder”. Psychiatry Grand Rounds, Duke University School of Medicine, Durham, North Carolina. February 22, 2018.
3. “The Strengths-Based Model of Neurodiversity and the Stanford Neurodiversity Project”. Neurology Grand Rounds, Stanford University School of Medicine, Stanford, CA. August 30, 2019.
4. “DIALOGUE: “What is Neurodiversity? Who does Neurodiversity serve?” Psychiatry Grand Rounds, Stanford University School of Medicine, Stanford, CA. November 6, 2019.
5. “Neurodiversity in the Medical and Educational Settings.” Surgery Grand Rounds, Western Reserve Health Education (WRHE), Trumbull Regional Medical Center, Warren, Ohio. September 23, 2020.
6. “Neurodiversity in the Medical and Educational Settings.” Psychiatry Grand Rounds, University of California at San Francisco. October 6, 2020.

7. “The Stanford Neurodiversity Project – a Multi-faceted Approach to Advance Neurodiversity Advocacy and Research in Academic Psychiatry.” Psychiatry Grand Rounds, Brookdale University Hospital and Medical Center, Brooklyn, NY, September 10, 2021.
8. “Sex differences in Neurobiology of Adults on the Autism Spectrum.” Child & Adolescent Psychiatry Webinar Series, University College Dublin, Dublin, Ireland, January 7, 2022.
9. “The Stanford Neurodiversity Project – a Multi-faceted Approach to Advance Neurodiversity Advocacy and Research in Academic.” Primary Care Grand Rounds, San Mateo County Medical Center, San Mateo, California. April 6, 2022.
10. “Neurodiversity in the Medical, Educational, and Employment Settings”. Physical Medicine & Rehabilitation Grand Rounds, Stanford University School of Medicine, Stanford, CA. April 13, 2022.

National and Regional Meetings:

1. “The Changes in the DSM-5.” Presented in the 19th Annual Autism Awareness Conference, Bakersfield, California. March 14, 2014.
2. “Mapping the 'Traffic Lights' in the Brains of Children with Autism: Clues to Better Treatment.” Presented in the 8th Annual Autism Update, Stanford Autism Center at Lucile Packard Children’s Hospital. April 18, 2015.
3. “Pregnenolone Trial in Autism—a Neurosteroid Approach.” Presented in the 9th Annual Autism Update, Stanford Autism Center at Lucile Packard Children’s Hospital. May 7, 2016.
4. “Psychiatric and Medical Challenges in Adults with Autism Spectrum Disorder.” Presented in the “Accessing Health Care for Adults with Autism Panel” of the 2016 Annual Meeting of the Autism Society of America (San Francisco Chapter), Stanford, CA. December 3, 2016.
5. “Myths and Facts of Medication Treatments in Autism Spectrum Disorder.” Presented in the “Severe Behaviors Panel” of 2016 Annual Meeting of the Autism Society of America (San Francisco Chapter), Stanford, CA. December 3, 2016.
6. “Pharmacologic treatments of severe disruptive behaviors in autism.” Presented in the 2017 Annual Meeting of the Autism Society of America (San Francisco Chapter), Stanford, CA. December 2, 2017.
7. “Cannabis in the treatment of autism: Are we ready?” Presented in the 2017 Annual Meeting of the Autism Society of America (San Francisco Chapter), Stanford, CA. December 2, 2017.
8. “The Stanford Neurodiversity Project”. Research Workshop, 3rd Autism at Work Summit, Seattle, WA. April 24, 2018.
9. “Closing the Cannabis Gap: Epidiolex and Cannabidiol” Presented in the 2018 Annual Meeting of the Autism Society of America (San Francisco Chapter), Stanford, CA. November 17, 2018.
10. “Maximizing the Potential of Neurodiverse Students and Employees.” Presented in the Google Accessibility Week at Google Inc., Mountain View, CA. November 17, 2018.
11. “GABAergic Dysfunction and Socio-communicative Deficits in Adults with Autism Spectrum Disorder”. Presented on February 9, 2019 at the Bay Area Autism Consortium Annual Meeting, Redwood City, CA.
12. “Strengths-Based Model of Neurodiversity and Stanford Neurodiversity Project”. To be presented at “Strengths of Dyslexia: Entrepreneurship & Neurodiversity Symposium”, Stanford, California, March 4, 2019.

13. “Maximizing the Potential of Neurodiverse Students and Employees”. Presented at Autism Asperger’s Spectrum Coalition for Education, Networking and Development, San Francisco, California, March 16, 2019.
14. “Neurodiversity is Strength! The Power of Neurodiversity in School and at Work”. Presented at the Marin Autism Collaborative Annual Meeting, Novato, California, April 27, 2019.
15. “Neurodiversity is Strength: The Power of Neurodiversity in School and at Work”. Presented in the 5th Annual Neuroscience Conference of the Autism Tree Project Foundation, La Jolla, CA. November 1, 2019.
16. “The Strengths-Based Model of Neurodiversity at Stanford.” Bay Area Autism Consortium. February 21, 2020.
17. “Maximizing the Potential of Neurodiverse Learners by using the Strengths-Based Model of Neurodiversity.” Family Leadership Summit, Palo Alto Unified School District. Gunn High School, Palo Alto, CA. February 22, 2020.
18. “Maximizing the Potential of Neurodiversity at the Workplace.” Presented virtually at Google Research. November 17, 2020.
19. “Neurodiversity and Autism – Culture of Inclusion.” Presented virtually at Google Cloud. December 10, 2020.
20. “Managing Challenging Behaviors in Children on the Autism Spectrum.” Presented at the Northern California Regional Organization of Child & Adolescent Psychiatry (NCROCAP) 2021 Virtual Annual Conference, January 30, 2021.
21. “Innovating Patient-Centered Care by the Strengths-Based Model of Neurodiversity.” Presented virtually at the 2022 InnovatorMD Global Summit, San Francisco, California, January 7, 2022.
22. “The Neurodivergent Litigant.” Co-presented with Hon. Michelle S. Short, Judge of the Superior Court of California, County of Los Angeles. 2022 Family Law Institute, Judicial Council of California. April 29, 2022.
23. “Neurodiversity in the Workplace.” County of Monterey, Salinas, California. April 29, 2022.
24. “What is Neurodiversity?” Greater Cincinnati Federal Executive Board. Diversity & Inclusion committee. July 19, 2022.
25. “Neurodiversity in the Medical and Employment Settings”. Department of Environmental Health and Safety, Stanford University School of Medicine, Stanford, CA. August 17, 2022.
26. “Neurodiversity in the Medical and Employment Settings.” PRIDE BRG Speaker Series, OhioHealth Community Health Partnerships. September 14, 2022.
27. “Neurodiversity in the Workplace.” Development Command, US Army Research Laboratories. September 21, 2022.
28. “Neurodiversity: the New Diversity.” CWOQ, Stanford University Reunion Homecoming 2022. October 20, 2022.
29. “Sex differences in Neurobiology of Adults on the Autism Spectrum.” Neuroscience Seminar Series, Santa Clara University, Santa Clara, California, November 7, 2022.
30. Neurodiversity Research Initiative Invited Lectureship, Kent State University, April 21, 2023.

International Meetings:

1. “GABAergic Neurophysiology and Socio-communicative Abilities in High-functioning Adults with Autism Spectrum Disorder”. Presented in the Symposium titled “Emerging Therapeutic Targets against Autism Spectrum Disorder” in the 18th World Congress of Basic and Clinical Pharmacology, Kyoto, Japan. July 4, 2018.
2. “Maximizing the Potential of Neurodiverse Students and Employees through Specialized Program Development”. Presented at the VII Annual International Conference “Autism: Challenges and Solutions”, Moscow, Russia. April 10, 2019.
3. “The Stanford Neurodiversity Project”. Presented at the Neurodiversity at Work Roundtable at the United Nations Secretariat, New York on April 30, 2019.
4. *Keynote Presentation*: “The Strengths-Based Model of Neurodiversity and the Stanford Neurodiversity Project”. Presented at the Autism at Work Summit, Melbourne, Australia. July 25, 2019.
5. “Neurodiversity is Strength: The Power of Neurodiversity in School and at Work”. Presented in the Second International Conference on Autism, Kolkata, India. January 12, 2020.
6. “Neurodiversity and the Impact of COVID-19.” Presented virtually at the University College Dublin ACAP COVID-19 Summer School Webinar Series. August 7, 2020.
7. *Keynote Presentation*: “Maximizing the Potential of Neurodiversity in Higher Education.” Presented virtually at the II Formative Journey for Inclusion in Higher Education. Autistic Collective of the State University of Campinas, São Paulo, Brazil. June 15, 2022.
8. “Disability Bias: Consequences and Economic Impact.” DIFEST Global 2022. October 18, 2022.